Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02128581 · ClinicalTrials.gov registry record · Phase 1
A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02128581: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02128581 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02128581, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Exendin-(9,39) has been shown to have effects on beta-cell function, and after gastric bypass, to accelerate gastrointestinal transit. - infused at rates of 300pmol/kg/min. Given that gastrointestinal transit is typically delayed by Glucagon-Like Peptide-1 (GLP-1) and also that this hormone causes decreased food intake through increased satiation, it is reasonable to expect an effect of Exendin-9,39 on appetite. This may help explain the effects of gastric bypass on food intake. To examine the effect of Exendin on food intake we propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion. We will examine the presence of gastrointestinal symptoms as well as food intake in the immediate aftermath of a test meal and the subsequent hours.
Interventions
- OTHER Saline
- DRUG Exendin-9,39
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-05 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02128581
The ClinicalTrials.gov registry entry for NCT02128581 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02128581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02128581 about?
NCT02128581 is a clinical study titled "A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake". Exendin-(9,39) has been shown to have effects on beta-cell function, and after gastric bypass, to accelerate gastrointestinal transit. - infused at rates of 300pmol/kg/min. Given that gastrointestinal transit is typically delayed by Glucagon-Like Peptide-1 (GLP-1) and also that this hormone causes d...
What is the current status of trial NCT02128581?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-05. Estimated completion is 2019-07.
What interventions are being tested in trial NCT02128581?
The interventions under investigation include: Saline (OTHER), Exendin-9,39 (DRUG).
Who is sponsoring clinical trial NCT02128581?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.